Company intelligence / Profile preview

Acobiom

Montpellier, Occitanie, Franceacobiom.com ↗

Ownership: Private
Employees: ~25
Development stage: Commercial

Overview

Acobiom has developed proprietary technology to identify RNA biomarkers from blood samples to create diagnostic tests that predict therapeutic response in diseases like pancreatic cancer. The company leverages genomics and transcriptomics expertise for personalized medicine. It holds patents related to experimental cancer drugs and monoclonal antibodies. Its diagnostics are used in both oncology and neurological disorders.

Therapeutic areas: OncologyNeurology
Modalities: Diagnostic test (blood-based)Biomarker discovery platform (genomics, transcriptomics)Monoclonal antibody (patent-related work)
Industry: Molecular Diagnostics

Drug pipeline

1 asset

GemciTest

Commercial

Indications: Pancreatic ductal adenocarcinoma

Partnerships

Not specifically listed; involved with local healthcare clusters in France

Beyond the preview

Go deeper on Acobiom.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acobiom.

Explore the full profile